FS Development Corp. (FSDC) to Combine with Gemini Therapeutics

Biotech firm Gemini Therapeutics announced this morning that it has entered into a definitive merger agreement with FS Development Corp. (NASDAQ:FSDC) that would give it a pro forma valuation of $265.6 million. Gemini is a clinical stage precision medicine company developing treatments for age-related macular degeneration (AMD) by developing drugging strategies that are matched to
Read More